Is Celularity Stock a Good Investment?
Celularity Investment Advice | CELUW |
- Examine Celularity's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Celularity's leadership team and their track record. Good management can help Celularity navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Celularity's business and its evolving consumer preferences.
- Compare Celularity's performance and market position to its competitors. Analyze how Celularity is positioned in terms of product offerings, innovation, and market share.
- Check if Celularity pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Celularity's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Celularity stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Celularity is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Good | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Celularity Stock
Researching Celularity's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company recorded a loss per share of 0.87. Celularity had not issued any dividends in recent years.
To determine if Celularity is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Celularity's research are outlined below:
| Celularity is way too risky over 90 days horizon | |
| Celularity has some characteristics of a very speculative penny stock | |
| Celularity appears to be risky and price may revert if volatility continues | |
| Celularity has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 22.77 M. Net Loss for the year was (196.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Celularity has accumulated about 38 M in cash with (38.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from gurufocus.com: Celularitys Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell ... |
Celularity Quarterly Good Will |
|
Celularity's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.56) | (1.49) | |
| Return On Capital Employed | (2.51) | (2.39) | |
| Return On Assets | (1.36) | (1.30) | |
| Return On Equity | (4.79) | (4.55) |
Determining Celularity's profitability involves analyzing its financial statements and using various financial metrics to determine if Celularity is a good buy. For example, gross profit margin measures Celularity's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Celularity's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Celularity's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Celularity. Check Celularity's Beneish M Score to see the likelihood of Celularity's management manipulating its earnings.
Evaluate Celularity's management efficiency
The company has return on total asset (ROA) of (0.1463) % which means that it has lost $0.1463 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.5423) %, meaning that it generated substantial loss on money invested by shareholders. Celularity's management efficiency ratios could be used to measure how well Celularity manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -1.49 in 2024. Return On Capital Employed is likely to climb to -2.39 in 2024. At this time, Celularity's Non Currrent Assets Other are fairly stable compared to the past year. Total Current Assets is likely to climb to about 30 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 117.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.30 | 2.18 | |
| Tangible Book Value Per Share | 1.27 | 1.33 | |
| Enterprise Value Over EBITDA | (0.59) | (0.62) | |
| Price Book Value Ratio | 1.07 | 1.13 | |
| Enterprise Value Multiple | (0.59) | (0.62) | |
| Price Fair Value | 1.07 | 1.13 | |
| Enterprise Value | 109.2 M | 103.7 M |
Celularity benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Beta 0.509 |
Basic technical analysis of Celularity Stock
As of the 23rd of November, Celularity shows the Mean Deviation of 13.7, risk adjusted performance of 0.0904, and Downside Deviation of 19.34. Celularity technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Celularity downside deviation, treynor ratio, as well as the relationship between the Treynor Ratio and expected short fall to decide if Celularity is priced correctly, providing market reflects its regular price of 0.022 per share. As Celularity appears to be a penny stock we also recommend to validate its total risk alpha numbers.Celularity's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Celularity insiders, such as employees or executives, is commonly permitted as long as it does not rely on Celularity's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Celularity insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pecora Andrew L over two months ago Disposition of 153718 shares by Pecora Andrew L of Celularity at 10.21 subject to Rule 16b-3 | ||
Hariri Robert J over three months ago Disposition of 2084854 shares by Hariri Robert J of Celularity at 3.0 subject to Rule 16b-3 | ||
Fletcher Kyle over three months ago Disposition of 201 shares by Fletcher Kyle of Celularity at 0.7141 subject to Rule 16b-3 | ||
Brigido Stephen over three months ago Acquisition by Brigido Stephen of 153718 shares of Celularity at 10.23 subject to Rule 16b-3 | ||
Von Eschenbach Andrew C. over three months ago Acquisition by Von Eschenbach Andrew C. of 277778 shares of Celularity at 0.7503 subject to Rule 16b-3 | ||
Hariri Robert J over three months ago Acquisition by Hariri Robert J of 2084854 shares of Celularity at 0.8343 subject to Rule 16b-3 | ||
Beers David C over six months ago Acquisition by Beers David C of 250000 shares of Celularity subject to Rule 16b-3 |
Understand Celularity's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Celularity's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0904 | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 13.7 | |||
| Semi Deviation | 13.59 | |||
| Downside Deviation | 19.34 | |||
| Coefficient Of Variation | 949.5 | |||
| Standard Deviation | 21.13 | |||
| Variance | 446.47 | |||
| Information Ratio | 0.0991 | |||
| Jensen Alpha | 3.28 | |||
| Total Risk Alpha | (1.11) | |||
| Sortino Ratio | 0.1083 | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 110.24 | |||
| Value At Risk | (35.20) | |||
| Potential Upside | 46.53 | |||
| Downside Variance | 373.95 | |||
| Semi Variance | 184.76 | |||
| Expected Short fall | (25.90) | |||
| Skewness | 0.8836 | |||
| Kurtosis | 1.85 |
| Risk Adjusted Performance | 0.0904 | |||
| Market Risk Adjusted Performance | (0.24) | |||
| Mean Deviation | 13.7 | |||
| Semi Deviation | 13.59 | |||
| Downside Deviation | 19.34 | |||
| Coefficient Of Variation | 949.5 | |||
| Standard Deviation | 21.13 | |||
| Variance | 446.47 | |||
| Information Ratio | 0.0991 | |||
| Jensen Alpha | 3.28 | |||
| Total Risk Alpha | (1.11) | |||
| Sortino Ratio | 0.1083 | |||
| Treynor Ratio | (0.25) | |||
| Maximum Drawdown | 110.24 | |||
| Value At Risk | (35.20) | |||
| Potential Upside | 46.53 | |||
| Downside Variance | 373.95 | |||
| Semi Variance | 184.76 | |||
| Expected Short fall | (25.90) | |||
| Skewness | 0.8836 | |||
| Kurtosis | 1.85 |
Consider Celularity's intraday indicators
Celularity intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Celularity stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0222 | |||
| Daily Balance Of Power | (0.80) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.0223 | |||
| Day Typical Price | 0.0222 | |||
| Market Facilitation Index | 5.0E-4 | |||
| Price Action Indicator | (0.0004) | |||
| Period Momentum Indicator | (0.0004) | |||
| Relative Strength Index | 50.06 |
Celularity Stock media impact
Far too much social signal, news, headlines, and media speculation about Celularity that are available to investors today. That information is available publicly through Celularity media outlets and privately through word of mouth or via Celularity internal channels. However, regardless of the origin, that massive amount of Celularity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Celularity news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Celularity relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Celularity's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Celularity alpha.
Celularity Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Celularity can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Celularity Corporate Management
| Carlos Ramirez | SVP Relations | Profile | |
| Sharmila MD | Senior Safety | Profile | |
| CFA CFA | Chief Officer | Profile | |
| Tim Wilk | Senior Operations | Profile | |
| Ramji Krishnan | Chief Officer | Profile | |
| Bradley Glover | Ex COO | Profile | |
| CPA MS | Treasurer | Profile |
Additional Tools for Celularity Stock Analysis
When running Celularity's price analysis, check to measure Celularity's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celularity is operating at the current time. Most of Celularity's value examination focuses on studying past and present price action to predict the probability of Celularity's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celularity's price. Additionally, you may evaluate how the addition of Celularity to your portfolios can decrease your overall portfolio volatility.